- J&J sees Spravato sales surge as psychedelic competitors loomPsychedelics, chiefly Compass Pathways' COMP360, are unlikely to make an immediate dent in the sales of Johnson & Johnson’s depression drug Spravato, H.C. Wainwright’s Patrick Trucchio told BioSpace.BioSpace · 9d ago↗ source
- STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvalsPrediction markets have permeated the worlds of sports, politics, and reality television shows. Now, the biopharma industry could be next.STAT · 9d ago↗ source
- Updated: Sanofi, Arbutus file separate suits against mRNA vaccine makers over LNP tech patentsSanofi and Arbutus are each going to court over alleged violations of their respective mRNA delivery patents, adding to a growing list of companies making similar complaints. The French pharma is…